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Theidiopathicinﬂammatorymyopathies (IM)representaheterogeneous groupofautoimmunediseases,ofwhich dermatomyosi-
tis (DM),polymyositis (PM),and sporadic inclusion body myositis (IBM) are the most common. The crucial role played by tumor
necrosis factor alpha (TNFα) in the IM has long been recognized. However, so far, 18 other members of the TNF superfamily have
been characterized, and many of these have not yet received the attention they deserve. In this paper, we summarize current
ﬁndings for all TNF cytokines in IM, pinpointing what we know already and where current knowledge fails. For each TNF family
member, possibilities for treating inﬂammatory diseases in general and the IM in particular are explored.
1.Introduction
Theidiopathicinﬂammatorymyopathies(IM)arecharacter-
izedbydistinctimmuneeﬀectormechanisms.Dermatomyo-
sitis (DM) is a complement-mediated endotheliopathy asso-
ciated with perimysial inﬂammation and perifascicular mus-
cle ﬁber atrophy. In polymyositis (PM) and sporadic inclu-
sion body myositis (IBM), muscle ﬁbers are injured by auto-
aggressive immune cells which predominantly inﬁltrate the
endomysium [1]. Additional degenerative phenomena occur
in IBM muscle, such as muscle ﬁber vacuolation and deposi-
tion of β-amyloid and other ectopically localized proteins
[2]. Other less well-delineated IM include myositis-associa-
ted cancer or connective tissue diseases and immune-media-
ted necrotizing myopathy. Macrophages, dendritic cells
(DCs), and T-cells are prominently present in muscle tissues
of the diﬀerent IM. In DM, large numbers of helper T-cells
are found within the perimysial, often perivascular, inﬂam-
matoryinﬁltrates.InPMandIBM,activatedcytotoxicT-cells
surround and invade nonnecrotic muscle ﬁbers, while helper
T-cells are found at more distant parts of the inﬁltrates.
B-cell-mediated immunity is an important component of
DM/PM pathogenesis, and autoantibodies can be detected
in up to 70% of patients [3]. The most common is Jo-1,
an antihistidyl-tRNA-synthetase, but more autoantibodies
directed against aminoacyl-tRNA-synthetases or other mus-
cle antigens are continuously being described. Autoantibody
proﬁles are associated with clinical subsets of patients [4]. In
IBM on the other hand, humoral autoimmunity is a more
controversial subject. However, it has been established that
IBM muscle contains large numbers of plasma cells and
an environment permissive of ectopic lymphoneogenesis,
which suggests the possibility of local maturation of B-cells
and autoantibody production. Indeed, a recent report des-
cribes IBM-speciﬁc autoantibodies directed against a yet un-
identiﬁed muscle antigen [5].
The important role played by cytokines in the IM has
long been recognized [6] .I nt h i sr e s p e c t ,ak e yr o l ef o rt y p eI
interferon (IFN)-mediated innate immunity has been shown
inDMandPM[7,8].Inthispaper,thetumornecrosisfactor
(TNF) family will be systematically overviewed, discussing
current knowledge on their involvement in the IM and ex-
ploring whether they could represent appropriate targets for
future therapeutic intervention. TNF cytokines aﬀect im-
mune cell proliferation, diﬀerentiation, and survival. Up till
now, 19 members have been identiﬁed in man, and they
have been assigned systematic names starting from TNFSF1
to TNFSF18 based on the encoding genes. Ectodysplasin A
(EDA) 1 and 2 have not been assigned systematic names and
will not be discussed in this paper. Most TNF members2 Clinical and Developmental Immunology
are type II transmembrane proteins whose extracellular C-
terminal TNF homology domain can be cleaved oﬀ by spe-
ciﬁc metalloproteinases, generating soluble cytokines. The
TNF-like receptors (TNFR) are type I transmembrane pro-
teins of which cystein-rich domains are the hallmark struc-
tural motif [9].
2. TNFSF2—TNFα
TNFα or cachectin, the prototypic member of the TNF fami-
ly, is produced mainly by activated macrophages and T-
cells. TNFα activates T-cells, B-cells, and macrophages and
induces the expression of other cytokines and cell adhesion
molecules through interaction with its receptor TNF-R55
(TNFR1). The alternative receptor TNF-R75 (TNFR2) has
been shown to chieﬂy function as a concentrator at cellular
surfaces, transferring the cytokine to TNF-R55 [10]. TNFα
augments the activity of nuclear factor-κB( N F - κB) signaling
pathways [11].
In the IM, TNFα is by far the most studied cytokine of
its family. The endomysial and perimysial inﬂammatory cells
express varying levels, with macrophages being the primary
source of the cytokine. TNFα is also prominently expressed
in blood vessel endothelial cells of DM tissues [12–14]. The
soluble forms of the receptors TNF-R55 and TNF-R75 are
increased in DM/PM sera [15]. TNF-R75 expression is nota-
bly increased near inﬂammatory inﬁltrates in all IM and on
theperimysialandperifascicularbloodvesselendotheliumin
DM even remote from inﬂammation [12]. Polymorphisms
in the gene encoding TNFα have been linked to either an
increased risk of, or protection against, the development of
juvenile DM [16, 17].
Neutralization of TNFα is eﬃcacious for treating several
autoimmune diseases. The important catabolic role of TNFα
as a regulator of the chronic inﬂammation associated with
the IM has made it a therapeutic target for these diseases as
well. Fortunately, knocking out TNFα appears relatively safe
and does not seem to hamper skeletal muscle regeneration
[18]. Four agents, that generate excellent results in rheuma-
toid arthritis (RA) and Crohn’s disease, can be considered
for IM patients: (1) a mouse/human chimeric anti-TNFα
monoclonal antibody termed inﬂiximab (Remicade), (2) a
TNFα-neutralizing receptor fusion protein termed etaner-
cept (Enbrel), (3) a humanized anti-TNFα monoclonal anti-
body termed adalimumab (Humira), and (4) the humanized
polyethyleneglycol conjugated Fab anti-TNFα fragment cer-
tolizumab pegol (Cimzia). For the ﬁrst two compounds, re-
ports so far have revealed variable outcomes in IM patients.
Trial results are summarized in Table 1 [19–26]. Several
phase II clinical trials have been started up, but, in general,
studies suﬀer from low inclusion rate and notably high drop-
out rates mostly due to disease deterioration and adverse
events. However, it appears that anti-TNFα treatment could
be of beneﬁt to a subset of IM patients. The identiﬁcation
of responsive patients remains diﬃcult, as no speciﬁc marker
has been identiﬁed yet that may predict the therapeutic out-
come.
3.Other TNF Members Already Investigated to
Some Extentinthe IM
3.1. TNFSF1/3—LTα/β. Lymphotoxins (LTs) are versatile
cytokines. They are crucial for robust immune responses
and are key elements required for lymphoid organogenesis
and organization. LTα, also termed TNFβ,i ss e c r e t e da st h e
homotrimerLTα3,orcomplexedonthecellsurfacewithLTβ,
predominantly as LTα1β2h e t e r o t r i m e r s .L T α can bind to the
receptor LTβRa sw ella st ot h er ec e p t o r sT N F R 1a n dT F N R 2 .
LTβ signals through LTβR ligation only.
It appears that LTs are important factors orchestrating
sustained inﬂammation in the IM. LTα has been implicated
in the cytotoxic response of CD8+ T-cells towards nonnecro-
ticmuscleﬁbersinPM[27].LTβ is increasedinmuscletissu-
es of DM patients, where it localizes to blood vessels and
intramuscularfollicle-likestructures.Thelattercontainlarge
numbers of T-cells, B-cells, and DCs organized in functional
compartments [28]. Recent data also show that LTβ may well
be an early marker for muscle disease [29].
LTs have been pinpointed as important targets for sup-
pressing inﬂammation in autoimmune diseases. Studies
showedthatdepletorymonoclonalanti-LTαandthereceptor
antagonistLTβR:Iginhibitdiseaseinmurinecollagen-induc-
edarthritis[30,31].Inaddition,administeringLTβR:Iginhi-
bited T-cell-driven intestinal inﬂammation in murine in-
ﬂammatory bowel disease [32]. In human RA, synovial LTα
and LTβ expression is elevated [33], but targeting the expres-
sion by administering LTβR:Ig failed to meet clinical end
points in a phase IIb clinical trial. As TNFα and LTα share
the receptors TNFR1 and TNFR2, strategies targeting these
receptors inﬂuence the activities of both cytokines. There-
fore, the therapeutic eﬀects of competitive antagonists of
TNFR1 and TNFR2, namely, etanercept and lenercept, are
presumed to result from combined inhibition of TNFα and
LTα.
3.2. TNFSF4—OX40L. The primary source of the trans-
membrane glycoprotein OX40L, also termed CD252 or
gp34, are antigen presenting cells, and expression is further
induced when B-cells, DCs, T-cells, and macrophages be-
come activated. The cytokine promotes clonal expansion of
T-cells, leading to long-term T-cell survival and enhanced
memory T-cell development. The receptor OX40, also term-
ed CD134, is expressed on activated T-cells, B-cells, and vas-
cularendothelialcells.Proinﬂammatorycytokines,including
TNFα, can further augment the expression of the receptor.
The OX40/OX40L interaction provides a costimulatory sig-
nal for T-cells and enhances ongoing immune responses
drivenbyeitherhelperT-celltype1(Th1),Th2,orTh17cells
[34].
OX40 is present on mononuclear cells in the endomy-
sium and at perivascular sites in PM muscle. OX40 positive
cells are mostly CD4+ cells, few are CD8+ cytotoxic T-cells.
Autoaggressive immune cells invading nonnecrotic muscle
ﬁbers are invariably OX40 negative [35]. OX40L expression
has not yet been described in the IM.
BlockingOX40Lhasproducedstrongtherapeuticeﬀectsin
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Table 1: Tumor necrosis factor inhibitors for treating inﬂammatory myopathies: published trial results for inﬂiximab and etanercept.
Compound and treatment
regimen
Diagnosis/patients
continued to end point Follow-up time Clinical outcome
at end point Reference
inﬂiximab 6mg/kg 4-weekly or
more frequent R-JDM/5 32 to 130 weeks I (5/5) [19]
inﬂiximab 10mg/kg (week 0, 2,
6, 14)
R-DM/1
R-PM/4
R-IBM/4
16 weeks
NC (1/1)
I (2/4) W (2/4)
I (1/4) NC (3/4)
[20]
inﬂiximab 10mg/kg (week 0, 2,
4)
R-DM/1
R-PM/1 12 weeks I (1/1)
I (1/1) [21]
inﬂiximab 10mg/kg (week 20)
inﬂiximab 10mg/kg (week 14,
18, 22)
R-DM/1
R-PM/1 66 weeks I (1/1)
I (1/1) [22]
inﬂiximab 10mg/kg (week 0, 2,
6, 14, 22) PM/2 26 weeks I (2/2) [23]
inﬂiximab 8mg/kg (week 0, 2, 6) R-DM/1 6 weeks I (1/1)
inﬂiximab 10mg/kg (week 0, 2,
4, 6, 9) R-PM/1 69 weeks I (1/1) [24]
inﬂiximab 3mg/kg (week 0, 2, 6,
every 8) and etanercept 25mg
twice weekly
R-DM/1
R-PM/2 36 to 96 weeks PR (1/1)
I (2/2) [25]
etanercept 25mg twice weekly R-DM/1 56 weeks I (1/1) [26]
Abbreviations: dermatomyositis (DM), improved (I), inclusion body myositis (IBM), juvenile DM (JDM), no change (NC), partial response (PR),
polymyositis (PM), refractory DM/PM/IBM (R-DM/PM/IBM), worsened (W).
disease, which include inﬂammatory bowel disease [36]a n d
arthritis[37].NeutralizingantibodiestoOX40Larecurrently
being tested in phase II clinical trials for treating asthma.
3.3. TNFSF5—CD40L. CD40L, also termed CD154 or gp39,
isexpressedbyactivatedT-cells,mainlyontheCD4+ subsets.
Its receptor CD40 is present on antigen presenting cells and
on endothelial cells. CD40L positive T-cells activate mono-
cytes and upregulate adhesion molecules and monocyte
chemoattractant protein 1 (CCL2) production by blood
vessel endothelial cells [38].
TheCD40/CD40L systemseemstobeinvolvedintheim-
munopathogenesis of the IM. A subset of inﬂammatory cells
inIMtissuesexpressCD40L,ofwhichthemajorityareCD4+
cells.Also,partofthemuscleﬁbersinPM/DMtissuesexpress
CD40. In vitro IFNγ-stimulation of myoblasts induces CD40
expression, leading to increased levels of IL-6, IL-8, IL-15,
and CCL2 [39]. The induction of proinﬂammatory factors
through the CD40/CD40L system could contribute to T-cell
recruitment and activation found within IM muscle tissues.
CD40L/CD40 interaction engages antigen presenting
cells, provokes B-cell responses and enhances the production
of proinﬂammatory cytokines, pinpointing the interaction
as an important regulatory mechanism in inﬂammatory dis-
ease. In murine collagen-induced arthritis, for example, an
agonistic anti-CD40 antibody exacerbates disease [40], while
a blocking anti-CD40L antibody protects against disease
[41]. Phase I and II trials in humans have already been ini-
tiated, testing the eﬀects of a humanized anti-CD40L anti-
body in inﬂammatory bowel disease [42]. However, the de-
velopment of IDEC-131, another humanized monoclonal
anti-CD40L, is no longer pursued after a placebo-controlled
trial demonstrated no clinical activity in systemic lupus ery-
thematosus (SLE) [43].
3.4. TNFSF6—FASL. FasL is expressed on activated T-cells
and NK-cells. The cytokine comes in a 40kDa membrane-
bound and a 29kDa-soluble variant. Its receptor Fas, also
termed CD95 or apoptosis 1 (Apo1), is constitutively expres-
sed on many cell types. An alternative soluble receptor term-
ed decoy receptor 3 (DCR3) has been described, possibly
serving to counteract Fas function. Fas ligation leads to a
conformational change, which causes binding of death do-
main-containing adaptor proteins, subsequently activating
caspases and nucleases.
A role for the Fas/FasL system in muscle damage is sus-
pected. Proinﬂammatory in vitro conditions have been
shown to induce apoptosis in muscle cells, a process that can
be partially inhibited by an anti-FasL antibody [44]. How-
ever, apoptosis is not a prominent feature of IM, and data
concerning Fas/FasL expression appear somewhat confusing.
FasL was found absent from IM muscle tissue [45]o re x -
pressedonlybysomeT-cells[27,46].Fasexpressionhasbeen
reported with very diﬀerent frequencies, but the sarcolemma
ofregeneratingmuscleﬁbersseemstorepresentthemainsite
of immunoreactivity. Also, some nonnecrotic invaded mus-
cle ﬁbers in PM/IBM and some atrophic perifascicular
muscle ﬁbers of DM are Fas positive [45, 47, 48]. Serological
studies report unchanged FasL levels, while Fas levels were
signiﬁcantly higher in PM/DM patients compared to normal
controls [49]. The peripheral blood of DM patients contains
signiﬁcantly lower percentages of regulatory T-cells, but the4 Clinical and Developmental Immunology
fractionofFaspositivecellsissimilar,indicatingnoincreased
susceptibility of regulatory T-cells to FasL-mediated apopto-
sis [50].
The involvement of Fas/FasL interactions in human in-
ﬂammatory disease is complex. It has been shown that Fas/
FasL deﬁciencies are associated with the accumulation of
lymphocytes and establishment of autoimmune disease. In-
deed, a number of inﬂammatory diseases seem to be asso-
ciated with decreased serum levels of soluble FasL. Adminis-
teringDCsoverexpressingFasLresultedinprotectionagainst
murine collagen-induced arthritis [51] possibly through
elimination of autoreactive T-cells. Nonetheless, in RA
synovial ﬂuid, increased levels of soluble FasL have been
found [52]. More research is needed to unravel the precise
involvement of the cytokine in human diseases.
3.5.TNFSF7—CD27L. CD27L,alsotermedCD70,isexpres-
sed on T-cells, B-cells, and NK-cells. It is a T-cell costi-
mulatory molecule whose expression is upregulated upon
activation. CD27L regulates the formation of eﬀector and
memory T-cells and induces their secretion of cytokines.
In the B-cell compartment, CD27L promotes diﬀerentiation
into plasma cells and subsequent antibody production, com-
mitment to memory B-cell responses, and the formation of
germinal centers. The receptor CD27 is constitutively ex-
pressedonrestingT-cellsandisupregulateduponT-cellacti-
vation. In B-cells, CD27 expression is induced by antigen-
receptor activation.
Very limited data is currently available on CD27L ex-
pression in the IM. We do know that unlike in the series of
SLE patients, CD27L is not increased on peripheral CD4+
cells of a single DM patient, who was included as a disease
control in the study [53].
Under physiological conditions, expression of CD27L is
restricted and transient in nature. Thus, CD27L oﬀers a
potential mechanism to selectively target only the activated
cells of the immune system, B-cells in particular, potentially
avoiding generalized immunosuppression and overt toxicity.
Anti-CD27L was found to improve disease and reduce auto-
antibodies in murine collagen-induced arthritis [54].
3.6. TNFSF10—TRAIL. TNF-related apoptosis-inducing
ligand(TRAIL),alsotermed Apo2L, canbe expressed byvar-
ious cell types. It binds TRAIL receptors 1 to 4 and osteo-
protegrin (OPG), inducing target cell apoptosis.
Only one report is available that describes TRAIL in PM,
statingthatmanyinﬂammatorycellsareTRAILpositive[55].
TRAIL is expressed in the endomysial capillaries of healthy
skeletal muscle and patients alike.
TRAIL potentially dampens autoimmune responses by
silencing autoreactive T-cell populations and, therefore,
could be beneﬁcial to patients suﬀering from inﬂammatory
diseases. A study showed that a blocking anti-TRAIL mono-
clonalantibody,ontheonehand,exacerbatesmurineexperi-
mental autoimmune encephalomyelitis, while recombinant
TRAIL, on the other hand, suppressed disease [56]. Thus,
strategies delivering a soluble TRAIL equivalent may be
eﬀective in suppressing disease episodes. In addition, a hu-
man study identiﬁed TRAIL as a prognostic marker for
IFNβ-response in multiple sclerosis (MS). Upregulated con-
centrationsofTRAILinresponsetoIFNβ distinguisheddrug
responders from nonresponders [57].
3.7.TNFSF11—RANKL. Receptor activator of NF-κBligand
(RANKL), expressed on the membranes of T-cells, is also
called TNF-related activation-induced cytokine (TRANCE),
OPG ligand (OPGL), or osteoclast diﬀerentiation factor
(ODF). Two putative receptors for RANKL have been pro-
posed, being RANK and OPG. RANK is a transmembrane
receptor present on DCs and T-cells. OPG is a soluble secret-
ed decoy receptor for RANKL. RANKL acts in synergy with
TNFα, activating a cascade of intracellular signaling events
which lead to osteoclast activation.
In mice, RANKL mRNA is expressed in healthy skeletal
muscle [58], which points to a role in normal muscle physi-
ology. A study reported serum RANKL concentrations to be
signiﬁcantlyhigherandRANKlevelstobesigniﬁcantlylower
in juvenile DM than in healthy age-matched controls [59].
RANKL/RANK is of major pathophysiological impor-
tance in the bone and joint destruction associated with RA
[59], where RANK expression appears to be limited to the
sites of immune reaction. The development of compounds
that mimic OPG action may prevent osteoclast-mediated
bone loss in patients [60]. Denosumab (AMG-162), a mono-
clonal anti-RANKL antibody, is currently being tested for
treating RA.
3.8. TNFSF13—BAFF and APRIL. B-cell activating factor
(BAFF), also termed TNFSF13b or B-lymphocyte stimulator
(BLyS), is expressed on the surface of monocytes, DCs,
and activated T-cells. BAFF binds three receptors: trans-
membrane activator and calcium-modulating cyclophilin
ligand interactor (TACI), BAFF receptor (BAFFR), and B-
cell maturation antigen (BCMA). BAFF is crucial for B-cell
maturation and survival and antibody production by plasma
cells. In addition, BAFF regulates T-cell activation and
diﬀerentiation. A proliferation-inducing ligand (APRIL) or
TNFSF13 is homologous to BAFF and exists only as a
soluble homotrimer. APRIL binds TACI and BCMA and is
important for B-cell development and function [61].
Serological studies have shown that BAFF levels are sig-
niﬁcantly increased in DM patients [62]b u tn o ti nP M / I B M
[63]. BAFF levels in serum correlated with IL-7, IL-12, and
CXCL10 [64] and with Jo-1 expression, supporting a role for
BAFF in autoantibody production. In addition, BAFF tran-
scripts were found markedly upregulated in muscle extracts
from DM (12-fold), PM (14-fold), and IBM (21-fold) pa-
tients [65]. In DM muscle, BAFF localizes to the muscle
ﬁbers in perifascicular areas [66]. Interestingly, mononuclear
cells inﬁltrating IM muscle express IFNα [67], a potent BAFF
inducer. Serum APRIL levels were found unaltered in IM pa-
tients [64].
BlockingBAFFandAPRILpotentiallydiminishesautore-
active B-cells, which would interrupt B-cell diﬀerentia-
tion and prevent autoantibody production. Thus, BAFF
and APRIL represent appropriate targets for interventionClinical and Developmental Immunology 5
in autoimmune diseases with an important humoral
pathogenic component. B-cells are especially associated with
DM inﬁltrates, where IFNα expression could well be the trig-
ger to activate autoantibody production. In addition, diﬀer-
entiated plasma cells can also be encountered in PM/IBM
muscle samples [68].
The anti-BAFF monoclonal antibody belimumab has
been tested in two phase III trials for the treatment of SLE. In
both trials, belimumab met the primary endpoints, showing
signiﬁcant clinical improvement compared to standard of
care alone. LY2127399, another BAFF neutralizing antibody,
hase nt e r edp haseIItrialsf o rR A.A tacic ept,anI gfusio np r o-
tein of the extracellular domain of the TACI receptor that
binds BAFF and APRIL, has currently reached phase II/III
f o rt r e a t i n gS L E[ 69].
4.TNF Members Not Yet ExploredinIM
4.1. TNFSF8—CD30L. CD30L is expressed on the mem-
branes of activated T-cells, resting B-cells, and monocytes.
Interaction with its receptor CD30, expressed on T-cells,
and B-cells, leads to their proliferation and activation. In
inﬂammatory diseases, CD30L/CD30 interactions seem to
represent both deleterious and beneﬁcial eﬀects. A blocking
monoclonal anti-CD30L antibody aggravates allograft rejec-
tion in mice by suppressing regulatory T-cell function [70],
while soluble CD30-Ig fusion protein ameliorates murine
experimental colitis through inhibition of Th17 responses
[71]. Elevated levels of soluble CD30 have been observed in
autoimmune diseases such as RA [72]a n dS L E[ 73].
4.2. TNFSF9—4-1BBL. 4-1BBL is predominantly expressed
onactivatedantigenpresentingcellsandinteractswiththe4-
1BB receptor expressed early and transiently on activated T-
cells and on DCs. The 4-1BBL/4-1BB interaction is relevant
to the pathogenesis of inﬂammatory disease. In sera of RA
patients, soluble 4-1BB and 4-1BBL levels are increased and
correlate with disease severity [74]. Treatment with an
antagonisticanti-4-1BBantibodyreducesseverityofarthritis
in animal models, ameliorating inﬂammation, and the asso-
ciated B-cell responses [75].
4.3. TNFSF12—TWEAK. The multifunctional cytokine
TNF-like weak inducer of apoptosis (TWEAK) triggers
multiple and often seemingly conﬂicting cellular responses,
which range from cell proliferation to cell death. Moreover,
TWEAK signaling through the FN14 receptor [76] has an
impact on normal muscle functioning. In vitro, TWEAK
inhibits the diﬀerentiation of myoblasts to myotubes [77]
and induces the expression of proinﬂammatory CCL2 [78].
TWEAK knockout mice exhibit augmented muscle tissue
regeneration [79], while overexpression results in inhibited
myoﬁber regeneration and increased expression of proin-
ﬂammatory cytokines including TNFα,I L - 1 β,I L - 6 ,a n d
CCL2 [80–83]. The proinﬂammatory cytokines inducible
by TWEAK are important regulators of IM [84], which
warrantsfurtherexploration.Also,circulatingTWEAKlevels
are signiﬁcantly increased in other human autoimmune dis-
e a s e ss u c ha sM Sa n dS L E[ 85]. A TWEAK-neutralizing
monoclonal antibody ameliorates collagen-induced arthritis
in mice, reducing serum and joint CCL2 levels signiﬁcantly
[86].
4.4. TNFSF14—LIGHT. Lymphotoxin-related inducible lig-
and that competes for glycoprotein D binding to herpes sim-
plex virus entry mediator (HVEM) on T-cells (LIGHT), also
termed LTγ,bindsthereceptorsLTβR,HVEM,andthedecoy
receptor DCR3. LIGHT is expressed by activated T-cells and
immatureDCs,andisapotentT-cellcostimulatorymolecule
[87]w i t hp r o f o u n de ﬀects on T-cell-mediated disease [88].
LIGHT enhances Th1-mediated immune responses and in
vitro strongly induces CXCR3 ligands [89]. The predomi-
nance of Th1-mediated immunity and CXCL10 expression
have been demonstrated in the IM [90]. In synovial tissues
from RA patients, both LIGHT and its receptor HVEM are
expressed by CD68+ macrophages, and their interaction in-
duces the proinﬂammatory cytokines TNFα, IL-6, and IL-8
[91]. Blocking LIGHT activity signiﬁcantly reduces graft ver-
sus host disease [92, 93].
4.5.TNFSF15—TL1. TNF-like1(TL1),alsotermedvascular
endothelial growth inhibitor (VEGI), is expressed by macro-
phages, lymphocytes, and plasma cells. TL1 binding enhan-
ces the expression of IFNγ by T-cells [94] and induces apop-
tosis in endothelial cells. TL1 has been implicated in human
inﬂammatoryboweldisease,whereitisfoundtobeincreased
in macrophages, plasma cells and lymphocytes [95], and TL1
gene variants have been linked to disease susceptibility [96,
97].
4.6. TNFSF18—GITRL. Glucocorticoid-induced TNF re-
ceptor ligand (GITRL), also termed TNF-like 6 (TL6), is ex-
pressed by endothelial cells, DCs, macrophages, and B-cells.
Its receptor GITR is present on naive, activated, and regu-
latory T-cells that, upon ligation, proliferate and produce-
cytokines. In RA, both GITR and GITRL are expressed in
synovial macrophages that, in response to in vitro stim-
ulation with an anti-GITR monoclonal antibody, produce
TNFα, IL-6, IL-8, and CCL2 [98]. Agonistic anti-GITR
monoclonal antibodies exacerbate joint inﬂammation and
cytokine production [99].
5. Conclusions andFutureProspects
Oral corticosteroids are still standard treatment for DM and
PM, but they come with serious side eﬀect and incomplete
treatment responses. Patients anxiously await more selective
treatment options. Moreover, IBM patients do not respond
to the immunosuppressive and immunomodulatory drugs
currently available. A better understanding of the deleterious
and beneﬁcial eﬀects of the diﬀerent players that make up
the IM muscle microenvironment is necessary to aid the
development of novel routes for therapy. In addition, such
knowledge could provide markers to distinguish potentially
responsive from nonresponsive patients, better predicting
the outcome of costly immune interventions.6 Clinical and Developmental Immunology
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Figure 1:Potentialrolesfortumornecrosisfactorcytokinesinthemuscledamageassociatedwithdermatomyositis.Basedoncurrentknow-
ledge, a model is developed describing the possible involvement of tumor necrosis factor (TNF) cytokines in the sustained inﬂammation
in perifascicular regions of muscle. Activation of the complement system leads to membrane attack complex (MAC) deposition on blood
vessels and subsequent necrosis. Endothelial monocyte chemoattractant protein-1 (CCL2) recruits inﬂammatory cells that accumulate and
organize in perimysial areas. Lymphocytes organize into functional compartments and produce lymphotoxins (LTs), TNFα and CD40L,
whichfurtherrecruitresponsiveimmunecells fromthecirculation, leadingtothebuildupofperimysialinﬂammation.Dendriticcells (DCs)
produce IFNα, which stimulates muscle ﬁbers to secrete B-cell activating factor (BAFF). The latter activates B-cells that, in response, begin
to produce autoantibodies. TNFα, mostly produced by Th-cells, provokes muscle ﬁber atrophy and stimulates major histocompatibility
complex I (MHC-I) and expression of adhesion molecules.
In this paper, we summarized current knowledge on the
involvementoftheTNFsuperfamilyofcytokinesinIM,ﬁnd-
ing ourselves humbled by the lack of data regarding some of
them.TheTNFcytokinesrepresentplausibletherapeutictar-
gets for the IM, as they are regulators of the complex inﬂam-
matorycascadethatleadstosustainedinﬂammation.ForPM
and IBM, limited information is available for TNF cytokines
otherthanTNFα.However,forDM,apictureisslowlyemer-
ging in which TNF cytokines no doubt play a crucial role.
Based on current knowledge, we developed a model des-
cribing the TNF-mediated sequence of events that lead to-
the characteristic muscle damage, being blood vessel loss,
perifascicular muscle ﬁber atrophy, and inﬂammation
(Figure 1).
Selectively targeting individual TNF members provides
new promises and opportunities to develop more eﬃcacious
therapies for IM while avoiding the toxicity seen in existing
systemic anti-inﬂammatory therapeutics.
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